Defence Therapeutics (TSE:DTC) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Defence Therapeutics Inc.’s innovative ARM-X anti-cancer vaccine has demonstrated significant success in combating pre-established ovarian cancer in animal studies, achieving complete responses when used with an anti-PD-1 immune-checkpoint inhibitor. This advancement in Defence’s Accum® platform marks the fourth cancer model successfully targeted by their ARM-X vaccine, offering a promising outlook for future oncology treatments.
For further insights into TSE:DTC stock, check out TipRanks’ Stock Analysis page.
